Alnylam's gene-silencing drug meets main goal in late-stage study

Alnylam Pharmaceuticals Inc said on Wednesday its gene-silencing drug for treating a rare, painful disease met the main goal in a late-stage trial.

from Reuters: Health News https://ift.tt/2tU6GFb
via IFTTT